Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abreva patent

This article was originally published in The Tan Sheet

Executive Summary

FDA seeks comments on length of patent extension for Avanir Pharmaceuticals' docosanol cold sore cream in Feb. 28 Federal Register notice. Avanir applied for 1,825 days of patent term extension with the Patent & Trademark Office, which in turn requested FDA's assistance in determining patent's eligibility. FDA maintains applicable regulatory review period for Abreva is 3,270 days; of this time, 2,323 days occurred during the testing phase and 947 days occurred during the approval phase. Comments will be accepted through Aug. 27...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS093679

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel